Searched for
SOVALDI
Merck wins record $2.5 billion patent verdict against GileadThe judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than ha...- Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rightsLegal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata P...
- Government's patent grant to Gilead challenged in Delhi High CourtGilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its HepC drug Sovaldi, is "unmer...
- Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson add...
- Blockbuster Hepatitis C drug now under price controlDrug-pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has brought under price control revolutionary drug 'Sofosbuvir' pres...
- Mylan launches generic Hepatitis C drug in IndiaDrug firm Mylan NV has launched generic Harvoni tablets, used to treat Hepatitis C, under the brand name 'MyHep LVIR' in India.
- Indian medicine, at 1/100th cost, saves Aussie's lifeThe 61-year-old Australian, suffering from hepatitis C, desperately needed a drug called Sivoldi to reverse the life-threatening condition.
- Gilead adds ten new countries for Sovaldi access programmeGilead said that it has also updated the pricing structure for drugs that it will be selling through its partner.
- Americans want to pop made in India Sovaldi drug for 1 per cent of the costThe drug is showing up for sale alongside illegal goods and narcotics on the dark web, which can be accessed through identity-hiding softwa...
- Mylan launches hepatitis-C Sovaldi tablets in IndiaSovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.
- Dr Reddy's to launch Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Zydus Cadila launches Gilead's Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- US pipeline, MS drug key to Natco's futureIn 2012, the company secured India's first compulsory licence to launch the generic version of Nexavar, Bayer's drug for treating liver and...
- Natco Pharma ties up with Gilead Sciences for Hepatitis C drugNatco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.
- Patent row no hurdle for Gilead Pharma’s Sovaldi launchGilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- India’s refuses patent to Gilead for its drug SovaldiThe decision of the patent office comes at a time when India-US trade relations are seeing an uptick ahead of President Barack Obama’s visi...
- India warns Egypt companies against selling Sovaldi medicinesIt may also to be mentioned that their production of Sovaldi medicines is still in the R&D stages and have not gone into production yet.
- Hepatitis C medicine being imported for Rs 1 croreThe imported drug comes at around Rs 15 lakh a month, taking the cost to Rs 45-50 lakh for a three-month course.
- National Pharmaceutical Pricing Authority cuts prices of diabetes & heart-disease drugsThe biggest debate on price cuts is happening in the US with patients, insurers and the government joining in.
Load More
